Clearside Biomedical IncOn the above Weekly chart price action has corrected almost 90% since August 2021. A number of reasons now exist to be bullish , including:
1) A strong buy signal prints (not shown).
2) Regular bullish divergence .
3) Price action confirms support on past resistance.
4) Falling wedge breakout + bac
Clearside Biomedical, Inc.
0.8441USDR
−0.0344−3.92%
Last update at May 21, 21:53 GMT
USD
No tradesPre-market
Next report date
≈
August 18
Report period
Q2 2025
EPS estimate
−0.10 USD
Revenue estimate
505.57 K USD
−0.4077 USD
−34.35 M USD
1.66 M USD
61.36 M
About Clearside Biomedical, Inc.
Sector
Industry
CEO
George M. Lasezkay
Website
Headquarters
Alpharetta
Founded
2011
FIGI
BBG002D4D4X3
Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. Its SCS microinjector enables a simple, repeatable, in-office procedure to deliver treatments directly to the macula, retina, or choroid, potentially helping to preserve and improve vision in patients with serious eye diseases. Its pipeline includes CLS-AX, an Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
−8,750.00%
−6,650.00%
−4,550.00%
−2,450.00%
−350.00%
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
−12.00 M
−8.00 M
−4.00 M
0.00
4.00 M
Revenue
Net income
Net margin %
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
−9.00 M
−6.00 M
−3.00 M
0.00
3.00 M
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
−9.00 M
−6.00 M
−3.00 M
0.00
3.00 M
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
−20.00 M
0.00
20.00 M
40.00 M
60.00 M
Debt
Free cash flow
Cash & equivalents
No news here
Looks like there's nothing to report right now
CLSD High UpsideCLSD has been beaten like the redheaded step child over the last few months, but yesterday 2/24 may have been the bottom. Looking at the long term chart, this is a huge support level. RSI reading extreme oversold levels. Should be good for a bounce.
NLong

NLong

NLong

NLong

CLSD Harmonics: 1-2-3 Go!!!I was just looking at clsd and discovered this, much to my amazement. If you missed round one and round two, try for round three. Good luck and trade safely!
NLong

Clearside Biomedical Announces Positive Safety Results from CohoCLSD: Clearside Biomedical, Inc.
2021-06-15 07:05:00
Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
NLong

CLSD LongUptrend Consolidation
SMA200 as support
OBV> OBV34
WR% Crossed -80
Entry 2.47
Stop 2
Target 4.3
Risk management is much more important than a good entry point.
The max Risk of each plan should be less than 1% of an account.
I am not a PRO trader. I trade option to test my trading plan with sma
NLong

$CLSDEntry price : 3.80
Fundamentals :
- Sector: Medical - Biotech
- EPS % Chg (Last Qtr): 70%
- EPS % Chg (Previous Qtr): 15%
- 3 Year EPS Growth Rate: 0%
- EPS Est % Chg (Current Yr): 0%
- Sales % Chg (Last Qtr): 2334%
- Sales % Chg (Previous Qtr): 687%
- 3-Year Sales Growth Rate: 265%
- Ann
NLong

Cup and handle. Like if you agreeShould close near the upper resistance, to about 4.15.
I see a cup and handle. Do you see the same?
NLong

See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CLSD is 0.8441 USD — it has decreased by −3.92% in the past 24 hours. Watch Clearside Biomedical, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Clearside Biomedical, Inc. stocks are traded under the ticker CLSD.
CLSD stock has fallen by −5.07% compared to the previous week, the month change is a 1.64% rise, over the last year Clearside Biomedical, Inc. has showed a −36.53% decrease.
We've gathered analysts' opinions on Clearside Biomedical, Inc. future price: according to them, CLSD price has a max estimate of 8.00 USD and a min estimate of 3.00 USD. Watch CLSD chart and read a more detailed Clearside Biomedical, Inc. stock forecast: see what analysts think of Clearside Biomedical, Inc. and suggest that you do with its stocks.
CLSD reached its all-time high on Oct 10, 2016 with the price of 25.0800 USD, and its all-time low was 0.5600 USD and was reached on Aug 28, 2019. View more price dynamics on CLSD chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CLSD stock is 6.64% volatile and has beta coefficient of 0.73. Track Clearside Biomedical, Inc. stock price on the chart and check out the list of the most volatile stocks — is Clearside Biomedical, Inc. there?
Today Clearside Biomedical, Inc. has the market capitalization of 65.59 M, it has increased by 6.16% over the last week.
Yes, you can track Clearside Biomedical, Inc. financials in yearly and quarterly reports right on TradingView.
Clearside Biomedical, Inc. is going to release the next earnings report on Aug 18, 2025. Keep track of upcoming events with our Earnings Calendar.
CLSD earnings for the last quarter are −0.11 USD per share, whereas the estimation was −0.11 USD resulting in a −1.85% surprise. The estimated earnings for the next quarter are −0.10 USD per share. See more details about Clearside Biomedical, Inc. earnings.
Clearside Biomedical, Inc. revenue for the last quarter amounts to 2.33 M USD, despite the estimated figure of 183.86 K USD. In the next quarter, revenue is expected to reach 505.57 K USD.
CLSD net income for the last quarter is −8.22 M USD, while the quarter before that showed −7.31 M USD of net income which accounts for −12.55% change. Track more Clearside Biomedical, Inc. financial stats to get the full picture.
No, CLSD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 22, 2025, the company has 32 employees. See our rating of the largest employees — is Clearside Biomedical, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Clearside Biomedical, Inc. EBITDA is −25.59 M USD, and current EBITDA margin is −1.72 K%. See more stats in Clearside Biomedical, Inc. financial statements.
Like other stocks, CLSD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Clearside Biomedical, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Clearside Biomedical, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Clearside Biomedical, Inc. stock shows the sell signal. See more of Clearside Biomedical, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.